OR WAIT null SECS
Cytovance Biologics Inc. announces development and manufacturing deal with NeuroFx for stem-cell-derived cell-free therapy for strokes.
Cytovance Biologics, Inc., a contract development and manufacturer of mammalian and microbial biologics, announced on July 29, 2015 a development and manufacturing agreement with NeuroFx, an Indiana-based regenerative medicine company, to develop and manufacture stem-cell derived, cell-free therapy for neurological conditions.
"Stem cells have demonstrated promise in early clinical trials evaluating safety, feasibility, and effectiveness for treating stroke. The mechanism of action by which multipotent adult stem cells address the complex pathophysiology of stroke is not predominantly their ability to differentiate into cell types that replace tissues lost to injury, but occurs through soluble therapeutic factors secreted by these cells which promote survival and repair," says Wade Lange, M.S. (NeuroFx CEO).
Brian Johnstone, Ph.D., (NeuroFx Director of R & D), states, "Recognition of the critical function of mesenchymal stem cells' (MSC) paracrine factors has prompted investigation into many different disease models of conditioned medium (CM) obtained from culturing MSC. Studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-derived therapeutic factors, demonstrating a similar effect as with cell delivery."
NeuroFx is developing a cell-free therapeutic factor concentrate (TFC) derived from adult adipose (fat) stem cells. TFC harnesses the healing potential of adult stem cells while addressing therapeutic and practical shortcomings of stem cell therapies, the company reports.